



2929 N Commerce Parkway
Miramar, FL 33025

July 13, 2021

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attn: Abby Adams
Laura Crotty

**Re: HCW Biologics Inc.
Registration Statement on Form S-1
File No. 333-256510
REQUEST FOR ACCELERATION OF EFFECTIVENESS**

Acceleration Request

Requested Date: July 15, 2021
Requested Time: 4:00 p.m. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, HCW Biologics Inc. (the “**Company**”) hereby requests that the Securities and Exchange Commission (the “**Commission**”) take appropriate action to declare the Company’s Registration Statement on Form S-1 (File No. 333-256510) effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

The Company hereby authorizes William L. Hughes, who is an attorney with the Company’s outside legal counsel, Orrick, Herrington & Sutcliffe LLP, to orally modify or withdraw this request for acceleration.

The Company requests that it be notified of such effectiveness by a telephone call to Mr. Hughes at (415) 773-5720.

[Signature page follows]

Sincerely,

HCW BIOLOGICS INC.

By: /s/ Rebecca Byam

Name: Rebecca Byam

Title: Chief Financial Officer

cc: William L. Hughes, Esq, *Orrick, Herrington & Sutcliffe LLP*
Scott M. Iyama, Esq., *Orrick, Herrington & Sutcliffe LLP*
Hing C. Wong, *HCW Biologics Inc.*
Rebecca Byam, *HCW Biologics Inc.*